Overview

"Efficacy and Safety of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission: the SIMILAR Trial"

Status:
Unknown status

Trial end date:
2016-09-01

Target enrollment:

Participant gender:

Summary

The objective of this study is to compare the efficacy of Infliximab-Biosimilar to Infliximab-Innovator and to demonstrate its noninferiority, in patients with ulcerative colitis or Crohn's disease in remission under treatment with infliximab up to 3 months.

Phase:

Phase 4

Details

Lead Sponsor:

Onze Lieve Vrouwe Gasthuis

Collaborator:

Santeon

Treatments:

Infliximab